Daniel James George, MD

Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-4615
Email address daniel.george@duke.edu

Education and Training

  • Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
  • Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
  • M.D., Duke University, 1992

Grants

Publications

Bitting, Rhonda L., Patrick Healy, Daniel J. George, Monika Anand, Sung Kim, Tina Mayer, Carol Winters, et al. “Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.” Eur Urol Oncol 4, no. 6 (December 2021): 948–54. https://doi.org/10.1016/j.euo.2020.01.005.

PMID
32063492
Full Text

Tagawa, Scott T., Krishnan Ramaswamy, Ahong Huang, Jack Mardekian, Neil M. Schultz, Li Wang, Rickard Sandin, Stanislav Lechpammer, and Daniel J. George. “Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.” Prostate Cancer Prostatic Dis 24, no. 4 (December 2021): 1032–40. https://doi.org/10.1038/s41391-021-00318-3.

PMID
33612825
Full Text

Wheeler, Stephanie B., Lisa P. Spees, Bradford E. Jackson, Christopher D. Baggett, Lauren E. Wilson, Melissa A. Greiner, Deborah R. Kaye, et al. “Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.” Jco Oncol Pract 17, no. 12 (December 2021): e1895–1904. https://doi.org/10.1200/OP.20.01082.

PMID
34138665
Full Text

Autio, Karen A., Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, et al. “Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.” European Urology Open Science 34 (December 2021): 70–78. https://doi.org/10.1016/j.euros.2021.09.015.

PMID
34934969
Full Text

Emamekhoo, Hamid, Mark R. Olsen, Bradley C. Carthon, Alexandra Drakaki, Ivor J. Percent, Ana M. Molina, Daniel C. Cho, et al. “Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.” Cancer, November 16, 2021. https://doi.org/10.1002/cncr.34016.

PMID
34784056
Full Text

George, Daniel J., Krishnan Ramaswamy, Ahong Huang, David Russell, Jack Mardekian, Neil M. Schultz, Nora Janjan, and Stephen J. Freedland. “Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.” Prostate Cancer and Prostatic Diseases, November 3, 2021. https://doi.org/10.1038/s41391-021-00463-9.

PMID
34732856
Full Text

Tucker, Matthew D., Landon C. Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman, Emily N. Kinsey, Kristin K. Ancell, et al. “Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.” Biomarker Research 9, no. 1 (November 3, 2021): 80. https://doi.org/10.1186/s40364-021-00334-4.

PMID
34732251
Full Text

George, Daniel J., and David P. Dearnaley. “Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.” Future Oncol 17, no. 33 (November 2021): 4431–46. https://doi.org/10.2217/fon-2021-0575.

PMID
34409852
Full Text

Koontz, B. F., K. E. Hoffman, T. Oyekunle, D. J. George, T. Zhang, W. R. Berry, W. R. Lee, et al. “Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer.” In International Journal of Radiation Oncology, Biology, Physics, 111:e281, 2021. https://doi.org/10.1016/j.ijrobp.2021.07.902.

PMID
34701084
Full Text

Pages